A combination of a monoamine oxidase inhibitor and a h5-ht1b antagonist or partial agonist
CA 2302204 A1 · Owner: Berg, Stefan · Inventors: Thorberg, Seth-Olov; Berg, Stefan; Ross, Svante
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a combination of a first component (a) which is a monoamine oxidase inhibitor and a second component (b) which is selective h5- HT1B antagonist or partial agonist having formula (I) wherein X is CH2 O; Y , is CONH, NHCO; R1 is H, C1-C6 alkyl C3-C6 cycloalkyl; R2 is H, C1-C6 alkyl C1-C6 alkoxy, halogen; R3 is formula (II); R4 and R5 independently are H or C1- C4 alkyl, as racemate, R-enantiomer or S-enantiomer and said components (a) , and (b) being i n the form of free bases solvates or pharmceutically , acceptable salts thereof the preparation thereof, pharmaceutical formulations containing said combinations, use of and method of treatment of affective disorders …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 9, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 9, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 9, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.